Loading
Life sciences · Journal article
Biomedicines · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ovarian cancer remains difficult to cure because disseminated peritoneal disease, heterogeneity, and resistance to platinum and poly(ADP-ribose) polymerase inhibitors limit treatment durability. Adeno-associated virus (AAV) vectors offer sustained transgene expression and capsid and regulatory cassette engineering, but translation is constrained by incomplete tumor-selective delivery, limited cargo capacity, host immunity, and heterogeneous tumor states. We examine AAV-mediated therapy in the context of recurrent and drug-resistant ovarian cancer. We discuss receptor retargeting, intraperitoneal versus systemic delivery, suicide genes, cytokines, genome editing, tumor suppressor restoration, and secreted antiangiogenic payloads. The most extensive ovarian AAV precedent concerns antiangiogenic and vascular-normalizing approaches; EpCAM-directed delivery and PD-L1-targeted AAV-CRISPR provide early evidence. FOLR1-targeted IL-12 efficacy and immune response findings derive from engineered MC38 colorectal tumors, with ovarian-cell targeting demonstrated separately. Studies do not establish restoration of platinum or PARP inhibitor sensitivity or any clinical benefit in resistant ovarian cancer. Chemotherapy combinations have preclinical support, whereas combinations with PARP inhibitors, checkpoint inhibitors, and antibody-drug conjugates remain hypotheses requiring direct testing. We outline biomarker-informed patient selection, immunological barriers to redosing, manufacturing and regulatory requirements, and a staged clinical development framework. Translation requires clinically representative resistant models and independent validation of delivery, pharmacodynamic activity, and safety before durable benefit can be inferred.